Cell and gene therapies (CGT) are revolutionizing healthcare. But much work remains to be done. Most importantly: the development and manufacturing processes need to move from a black-box approach towards quality-controlled, measurable and efficient procedures.
Imec believes technology has a big role to play in achieving this transformation. Provided that we make the right choices. To find out what those choices are, we assessed the needs within the CGT community during a roundtable at Advanced Therapies Week in January 2023.
Moderated by Peter Peumans, imec’s health technologies CTO, major stakeholders from the life sciences industry, instrumentation companies, investors, and consulting firms talked about the major challenges today and in the future.
The key takeaways from that discussion are presented in this report. We hope they can be the starting point for further conversations about the role of deep tech in advancing one of the most exciting therapeutic domains.